Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or IIIB non-small cell lung cancer; excluding patients with N3 disease based on supraclavicular or contralateral hilar adenopathy, or significant pleural / pericardial effusion.
You may not be if
Patients for whom treatment is planned with a maximum dose of ≥ 66 Gy to the ipsilateral brachial plexus
Greater than minimal, exudative, or cytologically positive pleural effusions
≥ 10% weight loss within the past month
Prior invasive malignancy (with exceptions)
Prior radiotherapy to the region of the study cancer
Significant co-morbidities
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
Known allergic reactions to components of planned chemotherapy regimen
